Galimedix, Inc. | WebDisclosure

Basculer en Français

9551	Companies
188518	Keywords
120339	Articles
100656	Press releases

Home
Companies
Galimedix, Inc.

PRESS RELEASE

published on 12/23/2024 at 17:30, 11 months 26 days ago

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation

Galimedix Therapeutics Phase 2 Study GAL-101 Dry AMD Geographic Atrophy
BRIEF

published on 12/05/2024 at 13:33, 1 year ago

Galimedix Therapeutics lance une étude de phase 1 avec le GAL-101 oral

Étude De Phase 1 La Maladie D'Alzheimer GAL-101 Galimedix Thérapeutique DMLA Sèche
BRIEF

published on 12/05/2024 at 13:33, 1 year ago

Galimedix Therapeutics Initiates Phase 1 Study with Oral GAL-101

Alzheimer's Disease Galimedix Therapeutics GAL-101 Dry AMD Phase 1 Study
PRESS RELEASE

published on 12/05/2024 at 13:28, 1 year ago

Galimedix Therapeutics initiates Phase 1 study with oral small molecule, GAL-101, an amyloid beta (Aβ) aggregation modulator
Galimedix Therapeutics initiates Phase 1 study with oral small molecule GAL-101, targeting neurodegenerative diseases. Study focuses on safety, tolerability, and pharmacokinetics for Alzheimer's, dry AMD, and glaucoma treatments

Galimedix Therapeutics Neurodegenerative Diseases GAL-101 Alzheimer's Phase 1 Study
BRIEF

published on 06/10/2024 at 14:05, 1 year 6 months ago

Galimedix Therapeutics réunit son conseil consultatif scientifique pour l'étude de phase 2 du GAL-101

Étude Clinique De Phase 2 Conseil Consultatif Scientifique GAL-101 Galimedix Thérapeutique DMLA Sèche
BRIEF

published on 06/10/2024 at 14:05, 1 year 6 months ago

Galimedix Therapeutics Assembles Scientific Advisory Board for Phase 2 Study of GAL-101

Scientific Advisory Board Galimedix Therapeutics GAL-101 Phase 2 Clinical Study Dry AMD
PRESS RELEASE

published on 06/10/2024 at 14:00, 1 year 6 months ago

Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101
Galimedix Therapeutics forms Scientific Advisory Board of retina experts to guide Phase 2 study with GAL-101 eye drops for dry AMD, addressing unmet medical need

Scientific Advisory Board Galimedix Therapeutics Phase 2 Study Dry AMD Retina Experts
BRIEF

published on 03/08/2024 at 10:05, 1 year 9 months ago

Galimedix Therapeutics dévoile des données prometteuses sur le traitement de la maladie d'Alzheimer à l'occasion de l'AD/PD™ 2024

Développement Clinique GAL-201 La Maladie D'Alzheimer Effets Neuroprotecteurs Fonction Cognitive
BRIEF

published on 03/08/2024 at 10:05, 1 year 9 months ago

Galimedix Therapeutics Unveils Promising Data on Alzheimer’s Treatment at AD/PD™ 2024

Clinical Development GAL-201 Alzheimer’s Disease Neuroprotective Effects Cognitive Function
PRESS RELEASE

published on 03/08/2024 at 10:00, 1 year 9 months ago

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
Galimedix Therapeutics presents new scientific data at AD/PD(TM) 2024, showing neuroprotective effects of GAL-201 for Alzheimer’s disease treatment, targeting misfolded Aβ monomers to prevent toxic aggregation

Alzheimer's Disease Galimedix Therapeutics Neuroprotective Effects Scientific Data AD/PD 2024

Accesswire

Published on 12/19/2025 at 00:00, 35 minutes ago

LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
Published on 12/18/2025 at 23:10, 1 hour 25 minutes ago

Air T, Inc. Announces Closing of Regional Express Acquisition
Published on 12/18/2025 at 23:05, 1 hour 30 minutes ago

BlackBerry Reports Third Quarter Fiscal Year 2026 Results
Published on 12/18/2025 at 22:45, 1 hour 50 minutes ago

Stabilis Solutions Announces Multi-Year Marine Bunkering Agreement with Carnival Coprporation at Proposed Galveston LNG Liquefaction Facility
Published on 12/18/2025 at 20:50, 3 hours 45 minutes ago

Results of AGM

View all ACCESSWIRE

EQS Group

Published on 12/18/2025 at 22:05, 2 hours 30 minutes ago

Abivax fait son entrée au sein de l'indice Nasdaq Biotechnology
Published on 12/18/2025 at 22:05, 2 hours 30 minutes ago

Abivax to be Added to Nasdaq Biotechnology Index
Published on 12/18/2025 at 20:09, 4 hours 25 minutes ago

EQS-Adhoc: The Grounds Real Estate Development AG: Conversion of the EUR 17 million bond issued in 2023/2024 into a hybrid bond
Published on 12/18/2025 at 19:30, 5 hours 5 minutes ago

Prodware: COMMUNIQUE DU 18 DECEMBRE 2025 RELATIF A LA MISE A DISPOSITION DE LA NOTE EN REPONSE ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES DANS LE CADRE DE L’OFFRE PUBLIQUE DE RETRAIT
Published on 12/18/2025 at 19:30, 5 hours 5 minutes ago

Prodware: COMMUNIQUE DU 18 DECEMBRE 2025 RELATIF A LA MISE A DISPOSITION DE LA NOTE D’INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES , NOTAMMENT JURIDIQUES, FINANCIERE DE PHAST INVEST

Les Echos

Published on 12/18/2025 at 18:30, 6 hours 5 minutes ago

Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
Published on 12/18/2025 at 18:30, 6 hours 5 minutes ago

Schneider Electric finalise l’opération d’acquisition des 35% restants du capital de sa JV existante en Inde
Published on 12/18/2025 at 17:45, 6 hours 50 minutes ago

Cie du Bois Sauvage: Vernietiging eigen aandelen
Published on 12/18/2025 at 17:45, 6 hours 50 minutes ago

Damartex réaffirme son éligibilité au PEA-PME
Published on 12/18/2025 at 17:45, 6 hours 50 minutes ago

Cie du Bois Sauvage : Cancellation of own shares

View all LES ECHOS COMFI WIRE